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ABSTRACT
PERINEAL TALC USE AND RISK OF ENDOMETRIAL CANCER IN
POSTMENOPAUSAL WOMEN
May 2011
LORI CRAWFORD, B.A., HAVERFORD COLLEGE
M.DIV, HARVARD DIVINITY SCHOOL
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Susan R. Sturgeon

Purpose: Endometrial cancer is the most common female reproductive cancer in the
United States. Most known risk factors for endometrial cancer are either genetic or
related to exposure to unopposed estrogens; less is known about risk due to
environmental exposures. While a number of studies have examined the relationship
between perineal talcum powder use and ovarian cancer risk, only one study has
addressed the relationship with endometrial cancer risk. Methods: The Women’s Health
Initiative Observational Study, a prospective cohort study of 93,676 United States
postmenopausal women from 1993-2005, measured perineal powder use at baseline via
self-report. Cases of endometrial cancer were self-reported and confirmed by both local
and central physician adjudicators. Cox proportional hazards regression was used to
examine the association between perineal powder use and endometrial cancer, adjusting
for known risk factors. Results: Of the 48,912 women in our analysis, 25,181 (52%)
reported ever use of perineal powders. There were 452 incident cases of endometrial
cancer diagnosed during 366,872 person-years of follow-up. Overall, ever use of
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perineal powder was not significantly associated with increased risk of endometrial
cancer (hazard ratio 1.05, 95% confidence interval 0.87-1.27). However, use of any
perineal powder for 20 or more years was associated with a 30% increase in risk (hazard
ratio 1.30, 95% CI 1.01-1.67) compared to never users. Furthermore, use of powder on
both a diaphragm and the external perineal area was associated with a 39% increase in
risk of endometrial cancer compared to women who never used perineal powder (hazard
ratio 1.39, 95% CI 1.00-1.93). Conclusions: Cessation of perineal powder use,
particularly on a diaphragm, may help reduce the risk of endometrial cancer.
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CHAPTER 1
INTRODUCTION

In the United States, endometrial cancer is the most common female reproductive
cancer, with new cases developing in 23.5 women per 100,000 each year.1 Most cases
are diagnosed in women over 50 years old, while cases in women under 40 are very rare.
Between 2003 and 2007, the 65-69 age group had the highest incidence in the United
States, with 90.8 new cases per 100,000 women.1 While incidence is highest among
white women (24.4 cases per 100,000 women from 2003-2007), black women have the
highest mortality (7.2 black women per 100,000 from 2003-2007 vs. 4.1 per 100,000
women of all races).1 Treatments for endometrial cancer include radiation, surgery,
chemotherapy, and endocrine therapy.2 Five-year survival has ranged from
approximately 83-86% from 1992-2002.1
Though there are some genetic risk factors, most known risk factors for
endometrial cancer are related to exposure to estrogens. Early menarche, late
menopause, nulliparity, estrogen-only hormone replacement therapy, and obesity have all
been identified as risk factors for endometrial cancer.3 Oral contraceptives that combine
estrogen and progestin have a protective effect against endometrial cancer which persists
for many years after oral contraceptive use has ended.4 Cigarette smoking also has a
protective effect; however, the biological mechanism for the protective effect of smoking
is still unclear.5
One non-hormonal exposure that may increase the risk of endometrial cancer is
adult use of talcum powder in the genital and/or perineal area. Talc has been shown to
1

migrate through the female reproductive tract as far as the ovaries.6 Talc has also been
shown to have an inflammatory effect on human tissues.7 Talc may therefore contribute
to the risk of female reproductive cancers through chronic inflammation, which in turn
causes cellular stress and carcinogenic cell damage.8
To date, only one epidemiologic study has directly addressed the association of
perineal powder use with endometrial cancer and found that perineal powder use led to a
21% increased risk of endometrial cancer in postmenopausal women only.9 Because this
study did not assess duration of powder use, it may have had some misclassification of
exposure. In contrast, many epidemiologic studies have examined the risk of perineal
powder use in the development of ovarian cancer. A meta-analysis of sixteen
observational studies found that ever perineal powder use led to a 33% increase in the
risk of ovarian cancer. 10 However, in this meta-analysis the lack of a clear dose-response
relationship between increased frequency of powder use and ovarian cancer made this
association uncertain.10 To confirm the association of perineal powder use with increased
risk of endometrial cancer in postmenopausal women, it is necessary to replicate the
findings of the single previous study in other large cohorts of postmenopausal women.
Because approximately 40% of United States women have used powder for
genital and/or perineal hygiene, even a small talc-related increase in the risk of
endometrial cancer could contribute significantly to the number of endometrial cancer
cases.9 Therefore, we investigated the association between perineal powder use and
endometrial cancer using data from the Women’s Health Initiative Observational Study.
This large prospective cohort study of United States women contained data on 93,676
postmenopausal women.
2

CHAPTER 2
REVIEW OF THE LITERATURE

Biological Mechanisms of Perineal Talc Use on Endometrial Carcinogenesis
Unlike most risk factors for endometrial cancer, perineal talc use likely does not
increase risk through a hormonal pathway. Instead, talc may increase the risk of
endometrial cancer by inducing chronic inflammation, which in turn causes cellular
damage and eventual carcinogenesis.
To cause inflammation in the endometrium, talc from powder applied externally
to the genitals or perineum must first migrate through the female reproductive tract to the
uterus. Although such upward migration goes against gravity and the natural flow of
menstrual blood and cervical mucus, several studies have shown that talc particles can
migrate through the female reproductive tract as far as the ovaries.6,11,12 Consistent with
these findings, perineal talc use has been associated with an increased risk of ovarian
cancer. The fact that some studies have not found this association in women who have
had tubal ligation suggests that blocked fallopian tubes may prevent the migration of talc
particles to the ovaries.13,14 Because talc particles must migrate through the uterus to
reach the fallopian tubes and ovaries, these studies showing migration of talc to the
ovaries imply migration of talc to the uterus.
Once in the uterus, there are two different pathways by which talc can cause
inflammation. First, talc, the primary ingredient in talcum powder for cosmetic and
hygienic use, is mineralogically similar to asbestos, a known human carcinogen. 15
Because talc deposits in the environment are often found together with asbestos, talcum
3

powder produced before 1976 was frequently contaminated with asbestos.16 One of the
main mechanisms by which asbestos causes carcinogenesis is through a chronic
inflammatory response.17 Thus, the biological mechanism by which talc may increase
endometrial cancer risk may include inflammation caused by asbestos contamination.
Second, even when not contaminated by asbestos, talc has been shown to cause
granulomas in human tissue.18 Granulomas are nodules of inflammation caused by
immune reaction which can lead to a persistent inflammatory response in the affected
tissue.19
Inflammation, whether produced by granulomas, asbestos contamination, or direct
contact with talc, leads to several mechanisms that cause cellular damage. Oxidants
produced by the inflammatory process may damage DNA, particularly the tumor
suppressor genes.20 Chronic inflammation can also lead to the deregulation of cytokine
production in cells, which in turn leads to several carcinogenic factors: alteration of cell
growth, lessening of normal apotosis, and unfavorable changes in cell differentiation.21
In summary, biological evidence supports the hypothesis that perineal talcum
powder use may contribute to the risk of endometrial cancer. Talcum powder applied
externally migrates through the female reproductive tract, where it can cause chronic
inflammatory responses in endometrial and ovarian tissue. This chronic inflammation
can then cause several kinds of cellular damage, which in turn can lead to carcinogenesis.

4

Epidemiology of the Effect of Perineal Talc Use on Endometrial Cancer
To date, there has been only one study of perineal powder use and risk of
endometrial cancer.9 In contrast, epidemiological investigation into the role of talc in the
female reproductive system has been almost entirely focused on epithelial ovarian
cancer.8,10,11,13,14,16,18,19,22,23,24 Most of these studies show a small increased risk of ovarian
cancer with perineal powder use,10,11,13,16,18,19,22,23 but some studies have failed to find an
association.8,14,24 One meta-analysis by Huncharek and colleagues of 16 observational
studies found a 33% increased risk of ovarian cancer with perineal powder use overall
(RR 1.33, 95% CI 1.16-1.45), but the risk in the subset of hospital-based studies was not
significantly elevated (RR 1.19, 95% CI 0.99-1.41).10 Huncharek and colleagues
suggested that selection bias or confounding may have influenced the risk estimates of
the population-based studies, especially since a dose-response relationship was not
observed across studies.10 In short, although many studies have found an association
between perineal powder use and ovarian cancer, the association is weak and not
consistently observed.
To our knowledge, Karageorgi and colleagues are the only investigators who have
evaluated the association of perineal powder use with endometrial cancer.9 The authors
studied a subset of 66,088 women from the prospective Nurses’ Health Study cohort,
including 599 incident cases of endometrial cancer. Data on perineal powder use were
collected by questionnaire in 1982. Women were asked about their usual use of talcum,
baby, or deodorizing powder on the perineal area and on sanitary napkins. Women were
also asked to report their frequency of perineal powder use. Data were also collected on
known hormonal risk factors for endometrial cancer, such as menstrual and reproductive
5

history, oral contraceptive use, family history of uterine cancer, and cigarette smoking.
Cases of endometrial cancer were assessed by self-report and verified by review of
medical records. Women entered the study at a mean age of 48, and were followed for an
average of 16 years. The authors found a 13% increase in endometrial cancer risk for all
women who had ever used perineal powder compared to women who had never used
perineal powder; however, this association was only borderline significant (OR: 1.13,
95% CI 0.96-1.33). In postmenopausal women, the authors found a 21% increase in risk
with ever use (OR: 1.21, 95% CI 1.02-1.44) and a 24% increase in risk with use of
perineal powder at least once a week (OR 1.24; 95% CI 1.03-1.48).
Karageorgi and colleagues represented a very strong preliminary evaluation of the
risk of endometrial cancer associated with perineal powder use. However, this study did
have some limitations. Women were asked about their usual powder use, which may not
be consistent over time. and therefore lead to nondifferential misclassification of
exposure. Also, the authors lacked data on duration of powder use, and so were unable to
evaluate a possible dose-response relationship between duration of powder use and risk
of endometrial cancer.
Mills and colleagues examined the association of perineal powder use with risk
of ovarian cancer in a population-based case-control study conducted from 2000-2001 in
22 counties in central California.19 Cases in this study had a mean age at interview of
56.6 years, and controls had a mean age at interview of 55.0 years. A total of 256
incident cases were identified by hospital tumor registrars. Controls were defined as
women 18 years or older with at least one intact ovary and no prior diagnosis of ovarian
cancer. Controls were selected by random-digit dialing in the same geographic area and
6

frequency matched by race/ethnicity and age. Powder use was assessed in a telephone
questionnaire conducted by trained interviewers for both cases and controls. Overall, the
authors observed an odds ratio of 1.37 for ever use of perineal powder (95% CI
1.02-1.85) compared to never perineal powder use. However, stratifying the results by
tubal ligation status changed the risk estimates considerably: powder-using women with
tubal ligation had a non-significant 12% decrease in ovarian cancer risk (OR 0.88, 95%
CI 0.45-1.68), compared to powder-using women with no tubal ligation who had a 54%
increase in ovarian cancer risk (OR 1.54, 95% CI 1.10-2.16).
One strength of this study is that it measured both frequency (in times per month
or week) and duration (in number of years) of perineal powder use. Also, stratification of
results by tubal ligation points to a possible protective mechanism in which the passage
of talc from the genital area to the ovaries is interrupted by ligation of the fallopian tubes.
Limitations of the study include a small sample size and low participation rates (40% of
eligible cases and 57% of eligible controls) which may have led to selection bias.
Furthermore, results were not stratified by menopausal status, so an odds ratio for
postmenopausal women only was not calculated.
Gertig and colleagues evaluated the association of perineal powder use with risk
of ovarian cancer in 78,630 women, aged 30-55 at baseline, from the prospective Nurses’
Health Study cohort.14 The methodology of this study was similar to Karageorgi and
colleagues as discussed above: perineal powder use was assessed at baseline by
questionnaire, and cases were ascertained by self-report confirmed by medical records.
The authors found no significant association of ever perineal powder use with ovarian
cancer compared to never use (RR 1.09, 95% CI 0.86-1.37). Risk did not significantly
7

increase with increased frequency of powder use (RR 1.12, 95% CI 0.82-1.55), nor was
risk increased in women who had tubal ligation compared to women with no tubal
ligation (RR 0.97, 95% CI 0.71-1.32). The only borderline significant finding in this
study was a small increase in risk of invasive serous ovarian cancer in ever perineal
powder users compared to never users (RR 1.40, 95% CI 1.02-1.91).
As with Karageorgi and colleagues’ analysis of the Nurses’ Health Study cohort,
Gertig and colleagues benefitted from the large sample size, which gave them adequate
statistical power to detect even a relatively small increase in risk. The prospective nature
of the study also eliminated possible recall bias in the measurement of exposure.
However, as with Karageorgi and colleagues, this study was limited by a single
assessment of powder use and no information on duration of powder use. Results were
not stratified by menopausal status, so there is no estimate of ovarian cancer risk from
perineal powder use among postmenopausal women.
In summary, the majority of studies examining perineal powder exposure as a risk
factor for female reproductive cancer have focused on epithelial ovarian cancer. These
studies have tended to find that perineal powder use leads to a small but significant
increase in risk of ovarian cancer, possibly modified by tubal ligation. Only one study
has explored perineal powder use as a risk factor for endometrial cancer. This previous
study had many strengths, but lacked data on duration of perineal powder use. Additional
study is needed to further evaluate the risk of endometrial cancer associated with perineal
talc use in postmenopausal women.

8

Summary
Endometrial cancer affects more women in the United States than any other
cancer of the female reproductive system. Most research on endometrial cancer has
focused on hormonal risk factors; many of these factors, such as age at menarche or
menopause, are not possible for women to modify. As many as 40% of women in the
United States are current or past users of powder on the perineal area; this represents an
easily modifiable non-hormonal risk factor which, if eliminated, could reduce the burden
of endometrial cancer in the Untied States.
Perineal talcum powder use may increase the risk of endometrial cancer through
several inflammatory pathways. Previous studies have shown that externally applied talc
can migrate through the female reproductive tract as far as the ovaries; 6,11,12 this
migration would necessarily involve talc exposure of the endometrium. In the past, talc
has been contaminated with asbestos, a known carcinogen that produces an inflammatory
response in human tissues.15, 16, 17 Even pure talc has been shown to cause granulomas in
female reproductive tissues; in turn, granulomas can lead to chronic inflammation.18, 19
Inflammation interferes with cellular cytokine production, which can then cause several
carcinogenic changes in the cell.21
Epidemiologic data have long suggested an association between perineal powder
use and ovarian cancer, potentially caused by a chronic inflammatory response to talc in
ovarian tissue. Most epidemiologic data on endometrial cancer relate to the risk of
hormonal factors, rather than environmental exposures such as talc. Existing data, while
limited, suggest an association between perineal powder use and endometrial cancer.
More data are needed to further study this association.
9

Therefore, our study examined perineal powder use as a risk factor for
endometrial cancer among postmenopausal women from the large Women’s Health
Initiative Observational Study cohort.

10

CHAPTER 3
METHODS

Study Hypothesis
Specific Aim: We proposed to evaluate the association between perineal powder
use and the risk of endometrial cancer in postmenopausal United States women.
Hypothesis: Among United States postmenopausal women, adult perineal use of
powder is associated with an increased risk of endometrial cancer.
Study Design and Population
This study examined the association between perineal powder use and
endometrial cancer using the publicly available data set from the National Heart, Lung,
and Blood Institute’s Women’s Health Initiative Observational Study, a prospective
cohort study conducted in the United States from 1993 to 2005.
The Women’s Health Initiative Observational Study enrolled a cohort of 93,676
ethnically diverse women from 40 clinical centers in 24 states and the District of
Columbia.25 Enrollment began on October 1, 1993 and continued until December 31,
1998. This cohort consisted of women who had initially been screened for one or more
of the Women’s Health Initiative clinical trials, but who were ineligible or unwilling to
participate in the clinical trials. At baseline, women were eligible for inclusion in the
Observational Study if they were between 50 and 79 years old, postmenopausal, and
planning to reside in the same area for at least 3 years. Women were excluded if they
were participating in another clinical trial, were unlikely to survive 3 years due to
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medical conditions, or had conditions such as dementia, drug dependency, or alcoholism
that could interfere with study participation.
At baseline, study participants had a screening visit at which physical
measurements and blood samples were collected. 26 Participants also completed several
questionnaires at baseline to assess family history, medical history, reproductive history,
quality of life, and lifestyle/behavioral factors. An additional baseline questionnaire
measured various exposures of potential interest, such as physical activity, early life
exposures, and occupational exposures. After baseline data collection, participants were
mailed questionnaires annually to update their exposure information and to report
medical outcomes of interest. Participants had another physical examination and blood
collection approximately 3 years after enrollment in the study. Participants were
followed prospectively for 6 to 10 years, depending on their time of enrollment, until
March 2005. At the end of the study, 6.1% were deceased and 4.1% were otherwise lost
to follow-up. The annual follow-up rate was at least 94% for each year.
In our study, we excluded women with hysterectomy at baseline (n=39,429)
because they are not at risk of endometrial cancer. We also excluded women with a
history of cancer other than nonmelanoma skin cancer (n=5,355), as well as women who
had both hysterectomy and history of cancer at baseline (n=6,720), leaving 49,172
eligible postmenopausal women. Of these women, we excluded those with missing
follow-up time in the Women’s Health Initiative data set (n=260), leaving 48,912 women
in the final analysis.

12

Exposure Assessment
Perineal powder use was assessed at baseline by self-report on the Observational
Study Questionnaire.27 Women were asked three questions about their perineal powder
use. The first question was “Have you ever used powder on your private parts (genital
area)?” Women who answered yes were asked to specify duration of use: less than 1
year, 1-4 years, 5-9 years, 10-19 years, or 20 or more years. The second question was
“Did you ever use a diaphragm (a birth control device that fits over the opening of your
womb)?” Women who answered yes were asked “Did you ever use powder on your
diaphragm?” and, if yes, were asked to specify duration of use with the same categories.
Finally, women were asked “Did you ever use powder on a sanitary napkin or pad?”
Women who answered yes were asked to specify the duration of use with the categories
above. In this study, each of these ever/never variables was analyzed dichotomously,
with duration of use analyzed categorically to evaluate a possible dose-response
relationship. Women were also categorized according to how many different ways they
had used perineal powders externally and/or internally; duration of use for this variable
was assigned according to the maximum duration of use across all categories. Assessing
the exposure at baseline ensured that exposure to perineal powder occurred before the
development of endometrial cancer.
The baseline questionnaires of the Women’s Health Initiative Observational Study
asked about “powder” use, and not all cosmetic powders contain talc. As such, the
measurements of powder use in this study were considered surrogate measurements for
talc use.

13

Validity of Exposure Assessment
To test the reliability of self-administered questionnaires, a Measurement
Precision Study was performed in a subset of subjects in the Observational Study.28 In
this substudy, women were asked to repeat 4 of the 8 self-administered baseline
questionnaires approximately 3 months after enrollment. Of the 2,045 women selected
for the substudy, 1,092 repeated their questionnaires. Kappa statistics were calculated to
measure the reliability of subjects’ responses over time. However, a kappa statistic for
the questions on perineal powder use was not reported in the Measurement Precision
Study results, as the questionnaire including powder use was not one of the
questionnaires that was repeated. Measured kappa statistics ranged from as low as 0.44
for reported history of congestive heart failure to 1.00 for reported history of colorectal
cancer. Overall, the authors of the Measurement Precision Study stated that “most risk
factors were reliably reported.”29 No behavioral variables similar to powder use were
measured in the Measurement Precision Study. We are not aware of any other validation
or reproducibility studies for perineal powder use.

Outcome Assessment
Endometrial cancer was one of the five main cancer outcomes of interest in the
Women’s Health Initiative study. 30 Participants in the Observational Study were mailed
an annual questionnaire by which they self-reported clinical outcomes of interest. For all
reports of new diagnoses of endometrial cancer, the physician adjudicator at the subject’s
local clinic confirmed the diagnosis and sent relevant pathology reports and other medical
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record information to the WHI’s Clinical Coordinating Center. In this study, endometrial
cancer was analyzed as a dichotomous variable.

Validity of Outcome Assessment
Tumor registry coders at the Clinical Coordinating Center coded information
about each endometrial cancer case.30 Coding was supervised by a physician and a
cancer epidemiologist.30 Trained cancer coders at the Clinical Coordinating Center also
reviewed self-reported cases whose diagnosis was denied by the local physician
adjudicator. In at least 94% of endometrial cancer diagnoses, locally reported cases were
confirmed centrally.30 Both local and centralized adjudicators were blinded to exposure
status to avoid bias.30

Covariate Assessment
Data on family history, medical history, demographics, and other exposures were
collected by self-report on the Women’s Health Initiative Observational Study baseline
questionnaires.31 Physical measurements and blood samples were taken at baseline inclinic by certified staff. In this study, we considered covariates that are known protective
or risk factors for endometrial cancer: age, race, body mass index, number of live births,
age at menopause, oral contraceptive use, postmenopausal hormone use, and smoking
status (Table 1).9

15

Statistical Analysis
We used multivariate Cox proportional hazards regression models to estimate the
association of categories and duration of perineal powder use with endometrial cancer.
Follow-up time was measured in days. Women contributed person-time for analysis until
diagnosis of endometrial cancer, death, hysterectomy, loss to follow-up, or the end of the
study, whichever happened first.
The Women’s Health Initiative Observational Study data set contained data on
three separate categories of perineal powder use: genital, sanitary napkin, and diaphragm.
In addition, duration of use was measured separately within each of these categories. For
this study, we first considered a simple ever/never model of perineal powder use (Table
6). Any woman who had ever used perineal powder in any of the three categories was
considered an ever user. Because different exposures to perineal powder may have been
associated with different risk, we also modeled risk of endometrial cancer according to
type of use. Within each category of use, we estimated the risk associated with different
durations of use (Table 7). For women who used powder on a diaphragm, we repeated
the analysis of duration of use restricted only to women who had ever used a diaphragm.
Many women used perineal powder in more than one way, such as on both
genitals and diaphragm. Such combined uses may have led to increased exposure to
powder, and potentially to increased risk of endometrial cancer. As such, we modeled
risk of women’s total powder exposure across all categories in two different ways. In one
analysis, we estimated risk associated with using talc powder only externally, only
internally, or both externally and internally (Table 8). In an additional analysis, we
estimated risk associated with the duration of powder use across all categories of use
16

(Table 9). In this analysis, each woman was categorized according to her maximum
duration of powder use; for example, if she used powder on sanitary napkins for five
years and on a diaphragm for ten years, she was categorized as having ten years of
exposure.
To address potential confounding, we included covariates that have been
identified in previous studies as known risk and/or protective factors for endometrial
cancer. Age was included as a continuous variable. Because of the relatively small
number of cases among subcategories of nonwhite women, race was included as a
categorical variable of white and other. Similarly, because of the relatively small number
of cases among underweight women and women of normal weight, body mass index was
included as a categorial variable with three levels: underweight/normal (BMI < 25kg/
m2), overweight (BMI 25-30 kg/m2), and obese (BMI > 30kg/m2). Number of live births
was included as a categorical variable: 0, 1-2, and 3 or more. Age at menopause was
included categorically and based on quartiles of women in the data set: age 48 or
younger, age 49-50, age 51-53, and age 54 and over. Because the protective effects of
oral contraceptive use have been shown to endure for many years after cessation of use,
oral contraceptive use was included as an ever/never categorical variable.4
Postmenopausal hormone use was included categorically according to current status:
never used, past user, and current user. Smoking was also included categorically
according to current status: never smoked, past smoker, and current smoker. For each of
these covariates except age, we estimated the association with endometrial cancer using
Cox proportional hazards regression to approximate age-adjusted hazard ratios with 95%
confidence intervals (Table 5).
17

Variables as listed above were evaluated for inclusion in each model as potential
confounders, using backward selection based on changes in the coefficients of interest.
All covariates with a p-value of <0.25 were included in the preliminary multivariable
models, as well as variables of clinical interest. After each preliminary model was fit,
covariates were removed one at a time, and models with and without each covariate were
compared to determine if removal of the covariate changed the coefficient of the powder
variable by more than 15%. After removing nonsignificant variables from the
preliminary model, variables that had initially been excluded from the preliminary model
were reintroduced and similarly checked for significance (p-value < 0.10). Finally, we
added interaction terms to the models to assess possible effect modification. Interaction
terms with a p-value of >0.05 were removed. To assess possible effect modification,
models were stratified by age category and BMI category and evaluted for a 15% or
greater change in the coefficient of the powder variable.
In the final, fully adjusted multivariate models, we estimated hazard ratios and
95% confidence intervals for ever vs. never perineal powder use, for different
combinations of use, and for different durations of use both within and across categories
of use. Final models were adjusted for age, race, BMI, number of live births, age at
menopause, oral contraceptive use, postmenopausal hormone use, and smoking status.
For each model, the proportional hazards assumption was tested based on weighted
Schoenfeld residuals, and goodness-of-fit was assessed by plotting the Nelson-Aalen
cumulative hazard estimate for Cox-Snell residuals.
All analyses were performed using Stata v. 11.1 (StataCorp, College Station, TX).
When data were missing, analyses were performed on available data without imputation.
18

P-values of <0.05 were considered statistically significant; no adjustment was made for
multiple comparisons.
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CHAPTER 4
RESULTS

The final analysis included 48,912 women with 452 confirmed diagnoses of
endometrial cancer during the follow-up period between 1993 and 2005. Over 12 years
of follow-up, a total of 366,872 person-years were accumulated. At baseline, the average
age of all participants was 63 years, and approximately 85% of the women reported their
race as white. Of the 48,912 women in the final analysis, 25,181 (52%) reported ever use
of powder on genitals, sanitary napkin, and/or diaphragm (Table 1). Ever users of
perineal powders were on average one year younger than never users (mean age of 62.7
versus 63.7). Ever users were also slightly more likely to be white (87% versus 84%),
and more likely than never users to be obese (26% versus 21%). Ever users of perineal
powders reported more ever use of oral contraceptives (44% versus 39%). Ever users of
perineal powders were also slightly more likely to be past or current users of
postmenopausal hormones (51% versus 49%) and to have ever smoked (52% versus
47%). Ever and never users of perineal powders were similar in their number of live
births and age at menopause.
Tables 2, 3, and 4 present a more detailed breakdown of perineal powder use by
category of use (genital, sanitary napkin, and diaphragm) and duration of use, ranging
from never use to 20 or more years of use. A comparison of the most extreme category of
duration of use (20 or more years) to the never use category in each of the types of
perineal powder use showed a distribution similar to the overall ever/never use
distribution described above. Some notable differences occurred in the category of
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women who reported 20 or more years of use of powder on a diaphragm compared to
women who never used powder on a diaphragm (Table 4). Women in this extreme
category of diaphragm powder use were on average older than never users (67 years
versus 63 years), more likely to be white (94% versus 85%), less likely to be obese (18%
versus 24%), more likely to have had at least one live birth (96% versus 85%), less likely
to have used oral contraceptives (21% versus 41%), less likely to have used
postmenopausal hormones (45% versus 49%), and less likely to have never smoked (47%
versus 51%).
To examine the role of potential confounding factors, we estimated the ageadjusted hazard ratios for known risk or protective factors for endometrial cancer: race,
BMI, number of live births, age at menopause, oral contraceptive use, postmenopausal
hormone use, and smoking status. Table 5 presents the age-adjusted bivariate hazard
ratios with 95% confidence intervals for each of these covariates. Women who reported
belonging to a race category other than white had a significantly lower risk of
endometrial cancer (HR 0.47; 95% CI 0.33-0.68). Obese women also had a higher risk of
endometrial cancer compared to women who were of normal weight or underweight (HR
1.52; 95% CI 1.24-1.89). Past use of postmenopausal hormones was associated with an
increased risk of endometrial cancer (HR 1.43; 95% CI 1.07-1.90) and current use of
postmenopausal hormones further increased risk (HR 1.95; 95% CI 1.59-2.40). In ageadjusted bivariate models, number of live births, age at menopause, ever oral
contraceptive use, and smoking status were not statistically significantly associated with
differences in risk of endometrial cancer (Table 5). However, because of the clinical
significance of each of these factors, all multivariate powder use models were fully
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adjusted for age, race, BMI, number of live births, age at menopause, oral contraceptive
use, postmenopausal hormone use, and smoking status.
In both age-adjusted and multivariate-adjusted models, ever perineal powder use
was not statistically significantly associated with increased risk of endometrial cancer
(Table 6). This analysis included any category of perineal powder use as ever use:
genital powder, sanitary napkin powder, and /or diaphragm powder. This analysis did not
consider duration of perineal powder use.
Because the Women’s Health Initiative baseline questionnaire measured three
kinds of perineal powder use, we estimated risk of endometrial cancer associated with
each kind of use: genital use, sanitary napkin use, and diaphragm use. We also estimated
risk associated with different durations of each kind of perineal powder use in order to
determine a possible dose-response relationship. Table 7 presents a more detailed
breakdown of age-adjusted and multivariate-adjusted hazard ratios for endometrial cancer
associated with each category of perineal powder use and duration of use within these
categories. Genital powder use and sanitary napkin powder use were not statistically
significantly associated with increased risk of endometrial cancer, regardless of duration
of use, suggesting that for these categories of use there was no dose-response
relationship. However, diaphragm powder use of 20 or more years was associated with a
threefold risk of endometrial cancer compared to women who never used powder on a
diaphragm (multivariate-adjusted HR 3.02; 95% CI 1.97-4.63).
Use of perineal powder in more than one way may represent an increase in total
talc exposure. To examine risk associated with multiple uses of perineal powder, we
categorized women according to their different combinations of perineal powder use.
22

Table 8 presents age-adjusted and multivariate-adjusted hazard ratios for endometrial
cancer associated with different combinations of perineal powder use, regardless of
duration of use. Using powder externally on genitals only, sanitary napkin only, or on
both genitals and sanitary napkins was not associated with an increased risk of
endometrial cancer. Use of powder internally on a diaphragm only was associated with a
nonsignificant increase in risk of endometrial cancer compared to women who never used
perineal powder (multivariate-adjusted HR 1.24; 95% CI 0.85-1.81). However, women
who used powder on both a diaphragm and genitals and/or sanitary napkins (i.e. both
internally and externally) had a borderline significant 39% increased risk of endometrial
cancer compared to never users of perineal powder (multivariate-adjusted HR 1.39; 95%
CI 1.00-1.93).
We also assessed the risk associated with total duration of all perineal powder use
by categorizing women according to their maximum duration of any perineal powder use.
Table 9 presents age-adjusted and multivariate-adjusted hazard ratios for endometrial
cancer associated with the maximum duration of powder use across all categories of use.
Use of any kind of perineal powder for less than 19 years was not associated with
increased risk of endometrial cancer. Women who had used any kind of perineal powder
for at least 20 years had a borderline significant 30% increased risk of endometrial cancer
compared to never users of perineal powder (multivariate-adjusted HR 1.30, 95% CI
1.01-1.67).
To test for possible effect modification by BMI or post-menopausal hormone use,
all analyses were repeated to estimate strata-specific hazard ratios for each category of
BMI and postmenopausal hormone use status. Effect estimates within strata of BMI and
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hormone use status were not substantially different from pooled estimates. Furthermore,
we repeated each analysis excluding cases occurring within two years of baseline, to
control for the possibility that women may have begun or increased perineal powder use
in response to symptoms of endometrial cancer. Analyses excluding cases within two
years of baseline yielded similar results to analyses of the entire study cohort. Finally,
effect estimates were consistent when both category of powder use and duration of use
were included in a single model.
The proportional hazards assumption was tested in each model using weighted
Schoenfeld residuals. Global tests for each model yielded p-values of <0.05 for all but
the model of duration of diaphragm powder use (p=0.08), showing that the proportional
hazards assumption may not be met for these models overall. However, testing the
proportional hazards assumption within each model for each individual powder-related
variable consistently yielded p-values >0.05, showing that the proportional hazards
assumption is satisfied for these variables. Plots of the Nelson-Aalen cumulative hazard
estimate for Cox-Snell residuals of each model showed adequate goodness-of-fit.
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CHAPTER 5
DISCUSSION

The purpose of this analysis was to evaluate the association of perineal powder
use with risk of endometrial cancer in postmenopausal women. Overall, we found that
the risk of endometrial cancer differed depending on category and duration of perineal
powder use. Among women who used powder only on the genitals or sanitary napkins,
we found no significant increase in risk of endometrial cancer regardless of duration of
talc use. However, use of powder on genitals and/or sanitary napkins in combination
with diaphragm powder use was associated with a 39% increase in risk of endometrial
cancer. When duration of powder use was evaluated across categories of use, women
who used any perineal powder for 20 or more years showed a 30% increase in risk of
endometrial cancer. Furthermore, women who used powder on a diaphragm for 20 or
more years showed a threefold increase in risk of endometrial cancer. These associations
of endometrial cancer with duration of powder use were only evident in the highest
category of duration, and did not suggest a dose-response effect.
It is possible that perineal powder use is only associated with certain subtypes of
endometrial cancer. In a previous study, Reeves and colleagues classified the subtypes of
endometrial cancer in the Women’s Health Initiative Observational Study data set
according to the World Health Organization and International Society of Gynecological
Pathology guidelines outlined by Creasman and colleagues.32,33 The majority of cases
were of the endometrioid type. There were not enough cases of other types of

25

endometrial cancer to permit an analysis of risk by endometrial cancer subtype in our
study.
One limitation of this study is the potential for nondifferential misclassification of
exposure. Women reported their perineal powder use on a written questionnaire at
baseline; they may have misreported their perineal powder use for various reasons. The
questionnaire states that the questions relate to talc, baby powder, and deodorant powder.
It is possible that some women reporting perineal powder use did not use powders
containing talc, or used talc products only some of the time. Women may have
underreported their perineal powder use if they felt embarrassed about such use, or overreported their use if they felt that powder was necessary for genital hygiene. Some
embarrassment may have been avoided by using a written questionnaire in which women
did not have to speak about their perineal powder use to an interviewer. Also, the
questions on perineal powder use represented just a few personal questions in a lengthy
questionnaire that asked many personal questions; as such, these questions did not stand
out as particularly intrusive. A more likely source of misclassification of exposure is that
women may not accurately recall the duration of their perineal powder use, and therefore
report a greater or lesser exposure than their true exposure. Another likely source of
misclassification of exposure is that women may have changed their perineal powder use
over the course of follow-up; thus, their exposure at baseline may not reflect their current
level of powder use. Any of these nondifferential misclassifications of exposure, if
present, would have biased our results toward the null, reducing our estimate of the risk
of perineal powder use on endometrial cancer.
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Nondifferential misclassification of outcome was less likely to have affected our
study findings. Cases of endometrial cancer were ascertained first through self-report on
annual questionnaires. All reported cases were verified both by local study physicians
and trained adjudicators at the Women’s Health Initiative Clinical Coordinating Center.
Because of this extensive professional verification, it is unlikely that any false cases of
endometrial cancer were included in the analysis. It is possible that some cases were
missed, most likely because they were asymptomatic or because women had not yet
sought medical care for their symptoms. Missed cases occurring equally among the
exposed and unexposed would be a nondifferential misclassification of outcome, and
would bias our results toward the null. Such misclassification is only likely to have
occurred in a very small percentage of participants.
Selection bias in this study is possible, but unlikely to have significantly affected
our results. In this prospective cohort study, information on perineal powder exposure
was collected before any cases of endometrial cancer had occurred; therefore, selection
bias at the time of participant selection was not an issue. Selection bias due to loss to
follow-up is possible. Overall, the follow-up rates for the Women’s Health Initiative
Observational Study were high.34 The annual questionnaire response rate was over 94%
each year. At the end of the follow-up period, only 4.1% of participants had ended their
participation or otherwise been lost to follow-up. An additional 6.1% of study
participants were deceased at the end of the follow-up period; however, information on
the cause of death was collected for most participants either through local study
physicians or through the National Death Index. If participants lost to follow-up or
missed as cases differed significantly in both exposure and outcome status, then selection
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bias may have occurred. For example, if women who were both powder users and had
endometrial cancer were most likely to stop participating in the study, we would have
underestimated the association between powder use and endometrial cancer. Because the
percentage of women lost to follow-up was relatively small and participation rates are
unlikely to differ by both exposure and outcome status, the effects of selection bias from
loss to follow-up should have been minimal.
Effects of potential information bias should have been similarly minimal. If
women who used perineal powders were less likely to seek medical care for reproductive
system related symptoms, then they would not be counted among cases and our results
would have been attenuated. Conversely, if perineal powder users paid more attention to
their genital areas and were therefore more likely to seek medical care for reproductive
system related symptoms, they would be more likely to be diagnosed as cases and our
results would have shown an exaggerated risk of perineal powder use. Neither of these
situations seems likely to have occurred on a scale large enough to have influenced our
results significantly. To further reduce the possibility of information bias, both local and
central adjudicators who reviewed cases were blinded to exposure status.
The Women’s Health Initiative Observational Study data set contained
information on all of the major risk factors for endometrial cancer recognized in previous
literature, including exposures related to reproductive history and hormone use. We
adjusted for potential confounders that we found to be significant from our bivariate and
multivariate analyses, as well as factors known to increase or decrease risk of endometrial
cancer. Despite our efforts to adjust for confounders, it is possible that one or more
confounding factors was measured insufficiently, or that we have missed an unknown
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confounder. For example, socioeconomic status may be related both to powder use and
risk of endometrial cancer, and this variable was not included in our analysis. If women
of a lower socioeconomic status were more likely to use perineal powder, and women of
lower socioeconomic status were also more likely to develop endometrial cancer (perhaps
due to lesser access to health care), then we would have seen a false association between
powder use and endometrial cancer. Confounding that we have not adequately adjusted
for could have caused us to over- or underestimate the risk of endometrial cancer from
perineal powder use, depending on how the confounding variable affects this association.
Because we have adjusted for a comprehensive set of variables that includes all major
known risk factors for endometrial cancer, we do not think that any residual confounding
significantly affected our results.
The results of our study should be generalizable to all post-menopausal women in
the United States who are at risk for endometrial cancer. The biological mechanisms by
which talc exposure can cause endometrial cancer may be modified by genetic variation
that increases or reduces risk; however, our large cohort represents a genetically diverse
population. Internationally, the results should be generalizable in areas in which cosmetic
talc composition is similar to United States cosmetic talc (i.e. no contamination with
asbestos).
In our analysis, we found that 52% of women had reported ever perineal powder
use, which is higher than the approximately 40% reported in other studies.9,35 However,
this percentage is high because it includes more than one category of powder use. In our
analysis, the highest percentage of women reported genital powder use; at approximately
39% of study participants, this finding is consistent with prior literature.
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To date, only one other study has examined the risk of endometrial cancer
associated with perineal powder use.9 Karageorgi and colleagues studied this association
in the Nurses’ Health Study cohort, which consisted of both pre- and post-menopausal
women. Karageorgi and colleagues reported a small but significant increase in risk
among postmenopausal women (21% for ever vs. never use; 24% for regular use vs.
never use).9 Their study measured use of powder on the genitals and on sanitary napkins,
but not on diaphragms. Their study also measured frequency of powder use, but not total
duration of powder use. Because Karageorgi and colleagues measured frequency of
powder use and our study measured duration of powder use, it is not possible to exactly
compare the measures of associated risk. However, the strength of the association found
in both studies is similar. The strength of association that we report is also comparable to
the reported association between perineal powder use and risk of ovarian cancer from
several previous studies.10,11,13,16,18,19,22,23
One important finding in this study was the increased risk of endometrial cancer
associated with use of powder on a diaphragm, especially for durations of diaphragm
powder use of 20 or more years. There are two possible explanations for this finding.
First, use of powder containing talc on a diaphragm introduces the talc directly into the
reproductive tract, where the talc is then physically closer to the endometrium. Talc thus
introduced directly into the reproductive tract has a shorter distance to migrate to the
endometrium, compared to talc which is applied to the genitals externally. With a shorter
migration distance and closer physical contact, talc used on a diaphragm may thus have a
greater inflammatory and/or carcinogenic impact on the endometrium. Second, a
duration of 20 or more years measured at baseline in 1993 suggests that women with
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especially long durations of use were using perineal powder prior to 1976, the year in
which asbestos contamination of talcum powder ended in the United States. Prior to
1976, cosmetic talc was often contaminated with the known carcinogen asbestos,
possibly rendering pre-1976 talcum powders more carcinogenic than talcum powders
produced after that date.16
In summary, we found a small but significant increase in risk of endometrial
cancer associated with diaphragm powder use and with any perineal powder use of 20 or
more years. While these findings are mostly consistent with prior research, further study
is needed to evaluate both the diaphragm-specific risk of powder use and the exact
biological mechanisms of the association. Because approximately 40% of United States
women have used powder for perineal hygiene, even a small talc-related increase in risk
may contribute significantly to the number of endometrial cancer cases. The results of
this study help clarify the relationship of powder use with endometrial cancer, and point
to a risk factor that is easily modified to reduce risk of a common reproductive cancer.
Furthermore, if the association of pre-1976 powder use with endometrial cancer is indeed
linked with asbestos contamination, our study suggests that further efforts to remove
asbestos from cosmetic talc may be necessary in areas in which this contamination may
still persist.
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APPENDIX A
HUMAN SUBJECT PROTECTION

All data were collected from participants by the Women’s Health Initiative
Observational Study. At the time of enrollment, all participants signed two separate
informed consent forms: one for the Women’s Health Initiative study in general, and
another specifically for the Observational Study arm. These forms both contained
explanations of the purpose of the study, the role of participants, potential benefits and
risks, confidentiality, and the right to withdraw.
Our study used only de-identified data from the Women’s Health Initiative
Observational Study, and as such no additional participant consent was required.
Because the data contains no personally identifiable information, no security measures
were necessary to protect participant confidentiality. Additionally, this specific analysis
plan was approved by the University of Massachusetts Institutional Review Board.
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APPENDIX B
PERMISSION TO ACCESS DATA

Permission to access data is was granted by the National Heart, Lung, and Blood
Institute on November 24, 2010. A copy of the permission to access data follows.
Signed copies are on file at the University of Massachusetts and the National Heart,
Lung, and Blood Institute.
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APPENDIX C
TABLES

Table 1. Distribution of covariates by perineal powder use status (n=48,912): Women’s Health Initiative
Observational Study, 1993-2005.

Characteristic

Never perineal powder use
N=23,346
N
%
Mean ± SD

Ever perineal powder use
N=25,181
N
%
Mean ± SD

Age at baseline, years

23,346

25,181

Race

63.7 ± 7.5

62.7 ± 7.2

White
Other

19,464 83.6
3,808 16.4

21,776 86.7
3,332 13.3

BMI category
<25 kg/m2
25-<30 kg/m2
!30 kg/m2

10,813 46.3
7,668 32.9
4,865 20.8

10,219 40.6
8,314 33.0
6,648 26.4

Number of live births
0
1-2
3 or more

3,346 14.4
7,935 34.4
11,894 51.3

3,281 13.1
9,147 36.6
12,568 50.3

Age at menopause, years
"48
49-50
51-53
54+

6,452
5,183
5,108
6,603

27.6
22.2
21.9
28.3

6,784
5,591
5,677
7,129

26.9
22.2
22.6
28.3

Ever oral contraceptive use
no
yes

14,337 61.4
9,009 38.6

14,158 56.2
11,023 43.8

Postmenopausal hormone use
Never
Past
Current

11,968 51.3
3,004 12.9
8,350 35.8

12,330 49.0
3,311 13.2
9,522 37.8

Smoking status
Never
Past
Current

12,224 53.1
9,301 40.4
1,507 6.5

12,012 48.3
11,375 45.8
1,462 5.9

Abbreviations: BMI, body mass index; SD, standard deviation
NOTE: Total numbers may not sum to total n due to missing data.
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Table 2. Distribution of covariates by duration of genital powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
Genital powder use
Never
<1 year
1 - 4 years
5 - 9 years
10 - 19 years
20+ years
N=29,837
N=5,128
N=3,307
N=2,245
N=2,131
N=5,868
N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD
Age at baseline, years

29,837 63.7±7.3

5,128

61.8±7.2

3,307

61.8.±7.2

2,245

62.2±7.1

2,131

62.3±7.1

5,868

63.4±7.2

White
Other

25,202 (84.7)
4,542 (15.3)

4,393 (85.9)
721 (14.1)

2,794 (84.8)
502 (15.2)

1,963 (87.6)
279 (12.4)

1,832 (86.2)
293 (13.8)

5,048 (86.3)
799 (13.7)

BMI category
<25 kg/m2
25-30 kg/m2
>30 kg/m2

14,035 (47.0)
9,766 (32.7)
6,036 (20.3)

2,087 (40.7)
1,699 (33.1)
1,342 (26.2)

1,322 (40.0)
1,057 (32.0)
928 (28.0)

864 (38.4)
737 (32.8)
644 (28.8)

784 (36.8)
709 (33.2)
638 (30.0)

1,954 (33.3)
1,998 (34.1)
1,916 (32.6)

Number of live births
0
1-2
3 or more

4,137 (14.0)
10,318 (34.9)
15,155 (51.1)

721 (14.1)
1,827 (35.9)
2,543 (50.0)

485 (14.8)
1,193 (36.3)
1,605 (48.9)

290 (13.0)
863 (38.8)
1,073 (48.2)

287 (13.6)
759 (35.9)
1,070 (50.5)

689 (11.8)
2,117 (36.3)
3,023 (51.9)

8,136 (27.3)
6,619 (22.2)
6,555 (22.0)
8,527 (28.5)

1,394 (27.2)
1,142 (22.3)
1,197 (23.3)
1,395 (27.2)

908 (27.5)
741 (22.4)
770 (23.3)
888 (26.8)

610 (27.2)
483 (21.5)
512 (22.8)
640 (28.5)

579 (27.2)
459 (21.5)
484 (22.7)
609 (28.6)

1,589 (27.1)
1,337 (22.8)
1,265 (21.6)
1,677 (28.5)

18,104 (60.7)
11,733 (39.3)

2,715 (52.9)
2,413 (47.1)

1,790 (54.1)
1,517 (45.9)

1,212 (54.0)
1,033 (46.0)

1,189 (55.8)
942 (44.2)

3,469 (59.1)
2,399 (40.9)

Postmenopausal hormone use
Never
15,028 (50.4)
Past
3,884 (13.0)
Current
10,894 (36.6)

2,370 (46.3)
685 (13.4)
2,068 (40.3)

1,595 (48.3)
440 (13.3)
1,269 (38.4)

1,102 (49.1)
289 (12.9)
854 (38.0)

1,047 (49.2)
278 (13.0)
804 (37.8)

3,148 (53.7)
742 (12.7)
1,977 (33.6)

1,609 (49.3)
1,471 (45.0)
187 (5.7)

1,060 (47.8)
1,065 (48.1)
91 (4.1)

1,003 (47.6)
989 (46.9)
117 (5.5)

2,682 (46.3)
2,685 (46.3)
429 (7.4)

Race

p-value

<0.01
0.06

Age at menopause, years
48 and under
49-50
51-53
54 and over
Ever oral contraceptive use
No
Yes

<0.01

<0.01

0.57

<0.01

<0.01

Smoking status
Never
15,439 (52.5)
2,434 (48.1)
Past
12,137 (41.2)
2,335 (46.2)
Current
1,852 (6.3)
288 (5.7)
Abbreviations: BMI, body mass index; SD, standard deviation
NOTE: Total numbers may not sum to total n due to missing data.

<0.01
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Table 3. Distribution of covariates by duration of sanitary napkin powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
Sanitary napkin powder use
Never
<1 year
1 - 4 years
5 - 9 years
10 - 19 years
20+ years
N=38,046
N=2,939
N=2,443
N=1,595
N=1,603
N=1,917
N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD
Age at baseline, years

38,046 63.4±7.4

2,939

61.8±7.1

2,443

61.8±6.9

1,595

62.5±6.9

1,603

63.6±6.9

1,917

64.1±7.1

White
Other

25,202 (84.7)
4,542 (15.3)

2,567 (87.5)
367 (12.5)

2,148 (88.3)
285 (11.7)

1,371 (86.1)
221 (13.9)

1,336 (83.7)
260 (16.3)

1,493 (78.1)
418 (21.9)

BMI category
<25 kg/m2
25-30 kg/m2
>30 kg/m2

16,690 (43.9)
12,512 (32.9)
8,844 (23.2)

1,314 (44.7)
940 (32.0)
685 (23.3)

1,043 (42.7)
807 (33.0)
593 (24.3)

655 (41.1)
547 (34.3)
393 (24.6)

659 (41.1)
545 (34.0)
399 (24.9)

676 (35.2)
624 (32.6)
617 (32.2)

Number of live births
0
1-2
3 or more

5,062 (13.4)
13,309 (35.2)
19,407 (51.4)

408 (14.0)
1,041 (35.7)
1,464 (50.3)

379 (15.7)
896 (37.1)
1,141 (47.2)

261 (16.5)
583 (36.8)
6,741 (46.7)

226 (14.3)
591 (37.3)
768 (48.4)

282 (14.8)
679 (35.6)
947 (49.6)

Age at menopause, years
48 and under
49-50
51-53
54 and over

10,368 (27.3)
8,493 (22.3)
8,416 (22.1)
10,769 (28.3)

738 (25.1)
647 (22.0)
702 (23.9)
852 (29.0)

662 (27.1)
533 (21.8)
541 (22.1)
707 (29.0)

489 (30.7)
344 (21.6)
339 (21.2)
423 (26.5)

457 (28.5)
365 (22.8)
353 (22.0)
428 (26.7)

519 (27.1)
405 (21.1)
429 (22.4)
564 (29.4)

Ever oral contraceptive use
No
Yes

22,553 (59.3)
15,493 (40.7)

1,572 (53.5)
1,367 (46.5)

1,281 (52.4)
1,162 (47.6)

926 (58.1)
669 (41.9)

949 (59.2)
654 (40.8)

1,216 (63.4)
701 (36.6)

Postmenopausal hormone use
Never
19,144 (50.4)
Past
4,893 (12.9)
Current
13,975 (36.7)

1,330 (45,3)
390 (13.3)
1,217 (41.4)

1,085 (44.4)
342 (14.0)
1,015 (41.6)

764 (47.9)
220 (13.8)
610 (38.3)

871 (54.4)
221 (13.8)
510 (31.8)

1,097 (57.3)
255 (13.3)
562 (29.4)

1,221 (50.6)
1,070 (44.3)
124 (5.1)

747 (47.5)
730 (46.5)
94 (6.0)

786 (49.8)
701 (44.5)
90 (5.7)

925 (48.9)
820 (43.4)
146 (7.7)

p-value

<0.01

Race
<0.01

<0.01

0.19

0.03

<0.01

<0.01

Smoking status
Never
19,048 (50.7)
1,509 (51.9)
Past
16,130 (43.0)
1,240 (42.7)
Current
2,357 (6.3)
156 (5.4)
Abbreviations: BMI, body mass index; SD, standard deviation
NOTE: Total numbers may not sum to total n due to missing data.

<0.01
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Table 4. Distribution of covariates by diaphragm powder use (n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
Diaphragm powder use
Never
<1 year
1 - 4 years
5 - 9 years
10 - 19 years
20+ years
N=42,332
N=1,020
N=1,831
N=1,260
N=1,145
N=780
N(%)
Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD N(%) Mean ±SD
Age at baseline, years

42,332

63.2±7.4 1,020

62.2±6.8 1,831

62.0±6.4 1,260

63.6±6.4 1,145

65.0±6.1 780

Race

67.1±6.1

p-value

<0.01
<0.01

White
Other

35,637 (84.5)
6,564 (15.5)

873 (85.8)
144 (14.2)

1,648 (90.1)
180 (9.9)

1,148 (91.2)
111 (8.8)

1,061 (93.0)
80 (7.0)

731 (94.2)
45 (5.8)

BMI category
<25 kg/m2
25-30 kg/m2
>30 kg/m2

18,080 (42.7)
14,009 (33.1)
10,243 (24.2)

468 (46.0)
316 (31.0)
236 (23.0)

861 (47.0)
582 (31.8)
388 (21.2)

616 (48.9)
415 (32.9)
229 (18.2)

564 (49.3)
346 (30.2)
235 (20.5)

380 (48.7)
263 (33.7)
137 (17.6)

Number of live births
0
1-2
3 or more

6,186 (14.7)
14,607 (34.8)
21,222 (50.5)

99 (9.8)
384 (37.9)
531 (52.3)

147 (8.1)
767 (42.1)
907 (49.8)

92 (7.4)
514 (41.1)
645 (51.5)

61 (5.4)
434 (38.2)
640 (56.4)

28 (3.6)
329 (42.4)
419 (54.0)

Age at menopause, years
48 and under
49-50
51-53
54 and over

11,781 (27.8)
9,378 (22.2)
9,333 (22.0)
11,840 (28.0)

258 (25.3)
216 (21.2)
218 (21.4)
328 (32.1)

423 (23.1)
416 (22.7)
428 (23.9)
554 (30.3)

294 (23.3)
289 (22.9)
307 (24.4)
370 (29.4)

297 (25.9)
253 (22.1)
249 (21.8)
346 (30.2)

143 (18.3)
185 (23.7)
202 (25.9)
250 (32.1)

Ever oral contraceptive use
No
Yes

25,192 (59.5)
17,140 (40.5)

510 (50.0)
510 (50.0)

795 (43.4)
1,036 (56.6)

613 (48.7)
647 (51.3)

684 (59.7)
461 (40.3)

616 (79.0)
164 (21.0)

Postmenopausal hormone use
Never
21,602 (51.1)
Past
5,430 (12.8)
Current
15,264 (36.1)

462 (45.4)
160 (15.7)
396 (38.9)

709 (38.7)
265 (14.5)
856 (46.8)

524 (41.6)
175 (13.9)
561 (44.5)

500 (43.7)
165 (14.4)
479 (41.9)

427 (54.8)
90 (11.6)
262 (33.6)

849 (46.8)
880 (48.5)
84 (4.7)

540 (43.3)
660 (52.9)
47 (3.8)

509 (45.0)
580 (51.3)
41 (3.7)

363 (47.3)
375 (48.9)
29 (3.8)

0.06

<0.01

0.03

<0.01

<0.01

Smoking status
Never
21,464 (51.4)
448 (44.6)
Past
17,615 (42.2)
486 (48.4)
Current
2,685 (6.4)
70 (7.0)
Abbreviations: BMI, body mass index; SD, standard deviation
NOTE: Total numbers may not sum to total n due to missing data.

<0.01
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Table 5. Risk factors related to endometrial cancer (n=48,912): Women’s Health Initiative Observational
Study, 1993-2005.

Variable

Race

BMI category

Number of live births

Age at menopause (years)

Ever oral contraceptive use

Postmenopausal hormone use
status

Smoking status

Number of
cases

Person-years

Age-adjusted
hazard ratio

White
Other

417
32

312936
52431

1.00
0.47

0.33-0.68

<25 kg/m2
25-30 kg/m2
>30 kg/m2

192
104
155

160485
120363
85536

1.00
0.71
1.52

0.56-0.90
1.24-1.89

0
1-2
3+

68
166
215

50474
129341
183831

1.00
0.96
0.82

0.72-1.27
0.63-1.08

<48
49-50
51-53
54+

113
87
105
146

99494
81587
81781
103523

1.00
0.93
1.15
1.21

0.70-1.23
0.88-1.50
0.94-1.54

No
Yes

276
175

213250
153134

1.00
1.07

0.87-1.32

Never

174

183625

1.00

Past
Current

65
211

47547
134900

1.43
1.95

1.07-1.90
1.59-2.40

Never
Past
Current

240
190
17

183336
155931
22096

1.00
0.95
0.63

0.78-1.15
0.38-1.03

Abbreviations: BMI, body mass index; SD, standard deviation
NOTE: Total numbers may not sum to total n due to missing data.
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95% CI

Table 6. Hazard ratios and 95% CIs for ever vs. never perineal powder use and endometrial cancer
(n=48,912): Women’s Health Initiative Observational Study, 1993-2005.
All perineal powder use
Never

Ever
p-value*

All women
Number of cases
Person-years
Age-adjusted HR (95% CI)
Multivariate-adjusted HR (95% CI)†

207
174,127
1.00 (ref)
1.00 (ref)

241
189,459
1.11 (0.92-1.34)
1.05 (0.87-1.27)

<0.001
<0.001

Abbreviations: HR hazard ratio; CI confidence interval
* P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use,
postmenopausal hormone use status, and smoking status.
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Table 7. Hazard ratios and 95% CIs for duration of perineal powder use and endometrial cancer, by category of powder use (n=48,912):
Women’s Health Initiative Observational Study, 1993-2005.
Duration of powder use
Never
<1 year
1 - 4 years
5 - 9 years
10 - 19 years
20+ years
p-value*
Genital powder use
Number of cases
Person-years
Age-adjusted HR (95% CI)
Multivariate-adjusted HR (95% CI)†

283
49
28
15
18
59
223,409
38,604
24,739
16,886
15,963
44,079
1.00 (ref) 1.07 (0.79-1.45) 0.95 (0.65-1.41) 0.74 (0.44-1.25) 0.94 (0.58-1.51) 1.07 (0.81-1.42)
1.00 (ref) 1.02 (0.75-1.39) 0.89 (0.60-1.32) 0.70 (0.42-1.18) 0.89 (0.55-1.44) 1.02 (0.76-1.35)

<0.001
<0.001

Sanitary napkin powder use
Number of cases
Person-years
Age-adjusted HR (95% CI)
Multivariate-adjusted HR (95% CI)†

340
36
17
18
22
17
284,736
22,039
18,483
11,995
12,021
14,315
1.00 (ref) 1.45 (1.03-2.04) 0.82 (0.50-1.3) 1.30 (0.81-2.09) 1.53 (0.99-2.36) 0.98 (0.60-1.59)
1.00 (ref) 1.35 (0.95-1.92) 0.79 (0.49-1.29) 1.30 (0.81-2.09) 1.62 (1.05-2.50) 1.03 (0.63-1.67)

<0.001
<0.001

Diaphragm powder use
Number of cases
Person-years
Age-adjusted HR (95% CI)
Multivariate-adjusted HR (95% CI)†

371
11
13
15
13
23
317,591
7,653
14,011
9,495
8,654
5,889
1.00 (ref) 1.27 (0.70-2.32) 0.83 (0.48-1.44) 1.34 (0.80-2.25) 1.23 (0.71-2.14) 3.01 (1.97-4.59)
1.00 (ref) 1.29 (0.71-2.35) 0.79 (0.46-1.38) 1.30 (0.77-2.18) 1.09 (0.61-1.93) 3.02 (1.97-4.63)

<0.001
<0.001

Abbreviations: HR hazard ratio; CI confidence interval
* P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.
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Table 8. Hazard ratios and 95% CIs for categories of perineal powder use and endometrial cancer (n=48,912): Women’s Health Initiative
Observational Study, 1993-2005.

Categories of perineal powder use
No talc use

Genital and/or sanitary napkin

Diaphragm only

Diaphragm + genital and/or napkin
p-value*

All perineal powder use
Number of cases
207
Person-years
174,127
Age-adjusted HR (95% CI)
1.00 (ref)
Multivariate-adjusted HR (95% CI)† 1.00 (ref)

163
141,821
1.01 (0.82-1.24)
0.96 (0.77-1.18)

32
20,552
1.31 (0.91-1.90)
1.24 (0.85-1.81)

44
25,468
1.49 (1.07-2.06)
1.39 (1.00-1.93)

<0.001
<0.001

Abbreviations: HR hazard ratio; CI confidence interval
* P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.
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Table 9. Hazard ratios and 95% CIs for maximum duration of perineal powder use across categories and endometrial cancer (n=48,912): Women’s
Health Initiative Observational Study, 1993-2005.

Maximum duration of all powder use
Never

<1 year

1 - 4 years

5 - 9 years

10 - 19 years

20+ years
p-value*

All perineal powder use
Number of cases
Person-years
Age-adjusted HR (95% CI)
Multivariate-adjusted HR (95% CI)†

207
174,127
1.00 (ref)
1.00 (ref)

44
43
30
35
88
41,615
38,056
26,934
26,588
55,031
0.95 (0.69-1.32) 1.02 (0.73-1.42) 0.97 (0.66-1.43) 1.14 (0.80-1.63) 1.35 (1.05-1.73)
0.89 (0.63-1.24) 0.96 (0.68-1.34) 0.93 (0.63-1.37) 1.06 (0.74-1.53) 1.30 (1.01-1.67)

<0.001
<0.001

Abbreviations: HR hazard ratio; CI confidence interval
* P-value of likelihood ratio test comparing nested models
† Adjusted for age, race, body mass index category, number of live births, age at menopause, oral contraceptive use, postmenopausal hormone use status, and smoking status.

49

REFERENCES

National Cancer Institute Surveillance Epidemiology and End Results, http://
seer.cancer.gov
1

Adami H, Hunter D, Tricopoulos D. Textbook of cancer epidemiology, 2nd ed. New
York: Oxford University Press, 2008.
2

Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and
endometrial cancer risk: a meta-analysis. Obstet Gyecol 1995;85:304-13.
3

Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus.
Contraception 1991;43:557-79.
4

Yang HP, Brinton LA, Platz EA, et al. Active and passive cigarette smoking and the risk
of endometrial cancer in Poland. Eur J Cancer 2010;46:690-6.
5

Henderson WJ, Hamilton TC, Griffiths K. Talc in normal and malignant ovarian tissue.
Lancet 1979;1:499.
6

7

Wehner AP. Biological effects of cosmetic talc. Food Chem Toxicol 1994;32:1173-84.

Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian
cancer. J Natl Cancer Inst 1999;91:1459-67.
8

Karageorgi S, Gates MA, Hankinson SE, et al. Perineal use of talcum powder and
endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19,1269-75.
9

Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and
risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen
observational studies. Anticancer Res 2003;23:1955-60.
10

Venter PF. Ovarian epithelial cancer and chemical carcinogenesis. Gynecol Oncol
1981;12:281-5.
11

Heller DS, Westhoff C, Gordon RE, et al. The relationship between perineal cosmetic
talc usage and ovarian talc particle burden. Am J Obstet Gynecol 1996;174:1507-10.
12

Merrit MA, Green AC, Nagle CM, et al. Talcum powder, chronic pelvic inflammation
and NSAIDs in relation to the risk of epithelial ovarian cancer. Int J Cancer
2008;122:170-6.
13

Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian
cancer. J Natl Cancer Inst 2000;92:249-52.
14

Rohl AN, Langer AM, Selikoff IJ, et al. Consumer talcums and powders: mineral and
chemical characterization. J Toxicol Environ Health 1976;2:255-84.
15

50

Gates MA, Tworoger SS, Terry KL, et al. Talc use, variants of the GSTM1, GSTT1,
and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers
Prev 2008;17:2436-44.
16

Schins RP. Mechanisms of genotoxicity of particles and fibers. Inhal Toxicol
2002;14:57-58.
17

Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian
cancer. Am J Epidemiol 1997;145:459-65.
18

Mills PK, Riordan DG, Cress RD, et al. Perineal talc exposure and epithelial ovarian
cancer risk in the central valley of California. Int J Cancer 2004;112:458-64.
19

Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad
Sci USA 1995;92:5258-65.
20

Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer
2004;4:11-22.
21

Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of
ovarian cancer. Int J Cancer 1999;81:351-6.
22

Chang S, Risch HA. Perineal talc exposure and risk of ovarian carcinoma. Cancer
1997;79:2396-401.
23

Wong C, Hempling RE, Piver S, et al. Perineal talc exposure and subsequent epithelial
ovarian cancer: a case-control study. Obstet Gyencol 1999;93:372-6.
24

Langer RD, White E, Lewis CE, et al. The Women’s Health Initiative Observational
Study: baseline characteristics of participants and and reliability of baseline measures.
Am Epidemiol 2003; 13:S107-S121.
25

The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative
clinical trial and observational study. Control Clin Trials 1998; 19:61-109.
26

The Women’s Health Initiative Scientific Resources Website: Form Images.
http://www.whiscience.org/data/forms.php, Form 42.
27

28

Langer et al., p. S108.

29

Langer et al., p. S120.

Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication
methods in the Women’s Health Initiative. Ann Epidemiol 2003; 13:S122-S128.
30

31

Langer et al., p. S107-S108.

Reeves KW, et al. Obesity in relation to endometrial cancer risk and disease
characteristics in the Women's Health Initiative, Gynecol Oncol (2011), doi:10.1016/
j.ygyno.2011.01.027.
32

51

Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO
6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol
Obstet 2006 Nov; 95(Suppl 1):S105–43.
33

The Women’s Health Initiative Scientific Resources Website,
http://www.whiscience.org/about/os.php
34

35

Rosenblatt KA, Matthews WA, Daling JR et al. Characteristics of women who use
perineal powders. Obstet Gynecol 1998; 92:753-756.

52

